{
    "clinical_study": {
        "@rank": "154567", 
        "arm_group": {
            "arm_group_label": "Cardiapex device", 
            "arm_group_type": "Experimental", 
            "description": "Use of the Cardiapex device in the context of transapical TAVI procedures"
        }, 
        "brief_summary": {
            "textblock": "A prospective, multicenter, uncontrolled study to evaluate the safety and efficacy of the\n      Cardiapex percutaneous trans-apical access and closure system. The Cardiapex device intended\n      for percutaneous access and closure of the left ventricular apex in conjunction with\n      transapical Transcatheter Aortic Valve Implantation (TAVI)."
        }, 
        "brief_title": "Safety and Efficacy Study of the Cardiapex Percutaneous Trans-apical Access and Closure System", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Transapical Transcatheter Aortic Valve Implantation", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient scheduled for transapical TAVI\n\n          -  Patient \u2265 70 years of age\n\n          -  Patient able to give informed written consent\n\n          -  Patient able to attend follow up examinations\n\n        Exclusion Criteria:\n\n          -  Scheduled concomitant non-TAVI cardiac procedure\n\n          -  Patient with Left Ventricular Ejection Fraction (LVEF) < 30% at time of enrollment\n\n          -  Patient with known apical infarcted area\n\n          -  Patient with a distinct large vessel right at the anatomical apex9 (based on\n             pre-operative coronary angiography\n\n          -  Patients with known lung tissue surrounding the apex and possibly interfering with\n             the in-out puncture (based on preoperative gated CT assessment\n\n          -  Patient with contra-indications to transapical TAVI\n\n          -  Patient's inability to tolerate or comply with normal post-surgical drug regimen\n\n          -  Patient's inability to comply with required follow-ups, including echocardiography\n\n          -  Patient participation in other clinical trials within previous month"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "70 Years"
        }, 
        "enrollment": {
            "#text": "38", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01722591", 
            "org_study_id": "CLN-PRO-01"
        }, 
        "intervention": {
            "arm_group_label": "Cardiapex device", 
            "description": "Cardiapex percutaneous transapical access and closure system", 
            "intervention_name": "Cardiapex device", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 23, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bad Nauheim", 
                        "country": "Germany"
                    }, 
                    "name": "Kerckhoff Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany"
                    }, 
                    "name": "Hamburg University Heart Center"
                }
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Prospective, Multicenter, Uncontrolled Study to Evaluate the Safety and Efficacy of the Cardiapex Percutaneous Trans-apical Access and Closure System", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Successful performance of percutaneous transapical TAVI defined as: \"Successful percutaneous transapical access and deployment of a single prosthetic heart valve\"", 
            "safety_issue": "Yes", 
            "time_frame": "Outcome measure assessed during the TAVI surgical procedure - an average of 3 hours"
        }, 
        "removed_countries": {
            "country": "Canada"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01722591"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "\u226430 day apical bleeding requiring surgical intervention", 
            "safety_issue": "Yes", 
            "time_frame": "30 days"
        }, 
        "source": "Cardiapex Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cardiapex Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}